Comparative Performance of Four Staging Classifications to Select «High-Risk» Head and Neck Cutaneous Squamous Cell Carcinomas.
classification system
cutaneous squamous cell carcinoma
head and neck
oncology
prognosis
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
08 Jun 2023
08 Jun 2023
Historique:
received:
01
05
2023
revised:
26
05
2023
accepted:
06
06
2023
medline:
28
6
2023
pubmed:
28
6
2023
entrez:
28
6
2023
Statut:
epublish
Résumé
Many classifications exist to select patients with "high-risk" head and neck cutaneous squamous cell carcinoma (HNCSCC). To compare the performance of the Brigham and Women's Hospital (BWH) classification with the performance of the American Joint Committee on Cancer 8th Edition (AJCC8), the Union for International Cancer Control 8th Edition (UICC8), and the National Comprehensive Cancer Network (NCCN) classifications. In this single-center retrospective study, HNCSCC resected in a tertiary care center were classified as "low-risk" or "high-risk" tumors according to the four classifications. Rates of local recurrence (LR), lymph node recurrence (NR), and disease-specific death (DSD) were collected. The performance of each classification was then calculated in terms of homogeneity, monotonicity, and discrimination and compared. Two hundred and seventeen HNCSCC from 160 patients, with a mean age of 80 years, were included. For predicting the risk of any poor outcome and risk of NR, the BWH classification had the best specificity and positive predictive value. However, its concordance index was not significantly higher than that of the AJCC8 and UICC8 classifications. The NCCN classification was the least discriminant. This study suggests that the BWH classification is the most appropriate for predicting the risk of poor outcomes in patients with HNCSCC when compared with the NCCN, UICC8, and AJCC8 classifications.
Sections du résumé
BACKGROUND
BACKGROUND
Many classifications exist to select patients with "high-risk" head and neck cutaneous squamous cell carcinoma (HNCSCC).
OBJECTIVE
OBJECTIVE
To compare the performance of the Brigham and Women's Hospital (BWH) classification with the performance of the American Joint Committee on Cancer 8th Edition (AJCC8), the Union for International Cancer Control 8th Edition (UICC8), and the National Comprehensive Cancer Network (NCCN) classifications.
METHODS
METHODS
In this single-center retrospective study, HNCSCC resected in a tertiary care center were classified as "low-risk" or "high-risk" tumors according to the four classifications. Rates of local recurrence (LR), lymph node recurrence (NR), and disease-specific death (DSD) were collected. The performance of each classification was then calculated in terms of homogeneity, monotonicity, and discrimination and compared.
RESULTS
RESULTS
Two hundred and seventeen HNCSCC from 160 patients, with a mean age of 80 years, were included. For predicting the risk of any poor outcome and risk of NR, the BWH classification had the best specificity and positive predictive value. However, its concordance index was not significantly higher than that of the AJCC8 and UICC8 classifications. The NCCN classification was the least discriminant.
CONCLUSIONS AND RELEVANCE
CONCLUSIONS
This study suggests that the BWH classification is the most appropriate for predicting the risk of poor outcomes in patients with HNCSCC when compared with the NCCN, UICC8, and AJCC8 classifications.
Identifiants
pubmed: 37373623
pii: jcm12123929
doi: 10.3390/jcm12123929
pmc: PMC10299006
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
PLoS One. 2020 Sep 29;15(9):e0239586
pubmed: 32991600
JAMA Dermatol. 2019 Jul 1;155(7):819-825
pubmed: 30969315
Eur J Cancer. 2015 Sep;51(14):1989-2007
pubmed: 26219687
N Engl J Med. 2001 Mar 29;344(13):975-83
pubmed: 11274625
JAMA Dermatol. 2013 May;149(5):541-7
pubmed: 23677079
JAMA Dermatol. 2018 Apr 1;154(4):428-434
pubmed: 29516080
Am J Surg Pathol. 2019 Jul;43(7):975-983
pubmed: 31094931
Eur J Cancer. 2020 Mar;128:83-102
pubmed: 32113942
J Am Acad Dermatol. 2019 Aug;81(2):548-557
pubmed: 30227190
Curr Opin Oncol. 2020 Mar;32(2):129-136
pubmed: 31850970
J Invest Dermatol. 2021 Sep;141(9):2161-2169
pubmed: 33771528
Head Neck. 2021 Mar;43(3):884-894
pubmed: 33247523
J Am Acad Dermatol. 2017 Jun;76(6):1139-1145
pubmed: 28314684
J Eur Acad Dermatol Venereol. 2020 Jun;34(6):1202-1209
pubmed: 31587382
Eur J Cancer. 2020 Mar;128:60-82
pubmed: 32113941
Laryngoscope. 2005 Sep;115(9):1561-7
pubmed: 16148695
Dermatol Surg. 2021 Mar 1;47(3):313-318
pubmed: 33165065
J Immunother Cancer. 2022 Dec;10(12):
pubmed: 36455990
JAMA Dermatol. 2013 Apr;149(4):402-10
pubmed: 23325457
J Am Acad Dermatol. 2021 Feb;84(2):361-369
pubmed: 32344066